BioCentury | Sep 1, 2017
Clinical News

CoCrystal reports Phase I data for HCV candidate CC-31244

...CC-31244, dosed at 400 or 600 mg once daily or 200 mg twice daily, reduced HCV RNA...
BioCentury | Feb 16, 2017
Clinical News

Aptima HCV Quant Dx assay regulatory update

...infection and monitor viral load. The in vitro nucleic acid amplification test detects and quantifies HCV RNA...
BioCentury | Dec 30, 2016
Clinical News

JNJ-4178: Ph IIb OMEGA-1 started

...end of treatment; SVR4, SVR24, viral relapse, on-treatment failure, on-treatment failure, time to achieve undetectable HCV RNA...
BioCentury | Oct 31, 2016
Clinical News

Sofosbuvir/velpatasvir/voxilaprevir: Phase III data

...safety; SVR4, SVR24, proportion of patients with an SVR on treatment, change from baseline in HCV RNA...
BioCentury | Oct 31, 2016
Clinical News

Sofosbuvir/velpatasvir/voxilaprevir: Phase III data

...safety; SVR4, SVR24, proportion of patients with an SVR on treatment, change from baseline in HCV RNA...
BioCentury | Oct 31, 2016
Clinical News

Sofosbuvir/velpatasvir/voxilaprevir: Phase III data

...safety; SVR4, SVR24, proportion of patients with an SVR on treatment, change from baseline in HCV RNA...
BioCentury | Oct 31, 2016
Clinical News

Sofosbuvir/velpatasvir/voxilaprevir: Phase III data

...safety; SVR4, SVR24, proportion of patients with an SVR on treatment, change from baseline in HCV RNA...
BioCentury | Oct 31, 2016
Clinical News

Cobas MPX regulatory update

...The real-time PCR in vitro test detects HIV-1 Group M and O RNA, HIV-2 RNA, HCV RNA...
BioCentury | May 9, 2016
Clinical News

Sofosbuvir/velpatasvir/GS-9857: Phase II data

...sustained virologic response (SVR) 12 weeks after the end of treatment and safety; SVR4, SVR24, HCV RNA...
BioCentury | May 9, 2016
Clinical News

Sofosbuvir/velpatasvir: Phase III data

...sustained virologic response (SVR) 12 weeks after the end of treatment and safety; SVR4, SVR24, HCV RNA...
Items per page:
1 - 10 of 753